Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.
Last month, names like Sanofi, Pfizer, Abbott and Takeda were flying around as potential suitors for Mexico-based Representaciones e Investigaciones Medicas, aka Rimsa. But it's Teva that's emerged victorious in the field.
Big Pharma is having a dealmaking fiesta in Mexico, with companies such as Sanofi, Pfizer and Teva Pharmaceutical Industries considering buying local generic drugmaker Representaciones e Investigaciones Medicas, also known as Rimsa, to beef up business south of the border.
After scrambling to convert Namenda patients over to a newer, longer-lasting version of the med, Allergan certainly doesn't want generic competition to the updated version. And for now, it's dodged a bullet, by striking an accord with Amneal to keep its copy off the market for more than four years.
Belgium's UCB has had a tough time unloading its U.S. generic drug business, calling off a sale last year amid regulatory pushback over one of the unit's products. Now the company is closing one chapter and moving on to the next, selling the business to Lannett for $1.23 billion to lighten its load and refocus on high-growth areas.
Teva's $40.5 billion deal for Allergan's generics business, announced last week, was just the latest to hit a rapidly consolidating generics industry. And while the M&A bug is sweeping through the wider pharma industry, in generics, there's an added factor pushing copycats to join hands.
Earlier this year, Allergan saw its plans to ease the pain from Namenda generics spoiled by a U.S. appeals court. And now, those generics are here.
The FDA has issued AstraZeneca's least favorite form of draft guidance--the kind that helps other drugmakers develop copies of a blockbuster seller.
Two union funds are suing Novartis, claiming that the Swiss drugmaker used "sham" patent-infringement claims to delay a generic version of its blockbuster leukemia drug Gleevec. Though just the latest in a series of legal battles over drug patent settlements, it's the first attempt by purchasers to block one of those settlements, the plaintiffs' lawyers said.
Eli Lilly scored a victory in its patent battle for lung cancer blockbuster Alimta in Europe, as the Court of Appeal in London ruled against Actavis' plan to market copycat versions of the med.